指南与共识肝病

超重人群中MASLD及进展性肝纤维化的患病率与危险因素:对筛查指南的启示

Prevalence and Risk Factors Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Fibrosis Among Overweight Individuals: Implications for Screening Guidelines.
指南 / 共识 · Am J Gastroenterol · 2026-06-24

该横断面分析纳入220例40-75岁南加州社区超重成人,MRI质子密度脂肪分数定义MASLD(肝脂肪≥5%),磁共振弹性成像定义进展性纤维化(≥3.63 kPa)。52%患MASLD,其中7%有进展性纤维化;高甘油三酯血症是MASLD最强独立预测因子(OR 3.11),高血压次之(OR 2.51)。以任何心血管代谢危险因素触发评估可识别93.9%的MASLD病例,而仅用糖尿病触发仅识别40.5%。

要点

  • 超重者MASLD患病率52%,其中7%有进展性纤维化。
  • 高甘油三酯血症和高血压是MASLD最强独立预测因子。
  • 建议超重者合并任何心血管代谢危险因素即应评估FIB-4。

核心结论

  • 现行指南应扩展至超重且合并任何心血管代谢危险因素者作为Fibrosis-4 Index评估候选,而非仅限糖尿病。
  • 超重人群纤维化监测应优先关注糖尿病及西班牙裔人群。

研究设计与样本

  • 横断面分析,纳入220例40-75岁居住于南加州的社区超重成人,来自一项前瞻性研究。
  • MASLD定义为MRI质子密度脂肪分数测肝脂肪含量≥5%且无其他肝病、无或轻度饮酒;进展性纤维化定义为磁共振弹性成像≥3.63 kPa。

主要发现

  • 220例超重者(平均年龄56.8±9.6岁,50.9%男性)中52%患MASLD,其中7%有进展性纤维化。
  • 高甘油三酯血症是MASLD最强独立预测因子(OR 3.11,95%CI 1.42-6.81,P=0.005),高血压次之(OR 2.51,95%CI 1.21-5.23,P=0.014)。
  • 进展性纤维化的显著预测因子包括西班牙裔、糖尿病和低高密度脂蛋白。
  • 61%的超重MASLD患者无糖尿病。
  • 以任何心血管代谢危险因素触发评估可识别93.9%的MASLD病例,仅用糖尿病触发仅识别40.5%。

关键数值与推荐

  • MASLD定义:MRI质子密度脂肪分数肝脂肪含量≥5%,无其他肝病,无或轻度饮酒。
  • 进展性纤维化定义:磁共振弹性成像≥3.63 kPa。
  • 高甘油三酯血症预测MASLD的OR 3.11(95%CI 1.42-6.81,P=0.005)。
  • 高血压预测MASLD的OR 2.51(95%CI 1.21-5.23,P=0.014)。

临床怎么用

  • 对超重且合并任何心血管代谢危险因素者应进行Fibrosis-4 Index评估以筛查MASLD。
  • 纤维化监测应优先关注合并糖尿病的超重者及西班牙裔超重者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current American Association for the Study of Liver Diseases guidelines recommend evaluation for fibrosis in diabetes or medically complicated obesity, and screening for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with cardiometabolic risk factors (CMRFs), but they do not define which metabolic and other risk factors warrant screening in overweight individuals. We aimed to identify risk factors that should prompt liver disease assessment in overweight individuals. METHODS: This is a cross-sectional analysis of community-dwelling adults (aged 40-75 years) residing in Southern California and enrolled in a prospective study. MASLD was defined as liver fat content ≥5% measured by MRI proton density fat fraction in the absence of other liver diseases and with no or mild alcohol use; advanced fibrosis was defined as ≥3.63 kPa measured by magnetic resonance elastography. RESULTS: Among 220 overweight individuals (mean age 56.8 ± 9.6 years, 50.9% male), 52% had MASLD, of whom 7% had advanced fibrosis. Hypertriglyceridemia was the strongest independent MASLD predictor (odds ratio [OR] 3.11, 95% CI 1.42-6.81, P = 0.005), followed by hypertension (OR 2.51, 95% CI 1.21-5.23, P = 0.014). For advanced fibrosis, Hispanic ethnicity, diabetes, and low high-density lipoprotein were significant predictors. Notably, 61% of overweight individuals with MASLD did not have diabetes. Targeting overweight individuals with any CMRF for evaluation would identify 93.9% of MASLD cases, compared with only 40.5% when using diabetes alone as the screening trigger. DISCUSSION: Current guidelines should be expanded to include overweight individuals with any CMRF, not just diabetes, as candidates for Fibrosis-4 Index score assessment. Fibrosis surveillance among overweight individuals should prioritize those with diabetes, as recommended by current guidelines, as well as people of Hispanic ethnicity.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Mironova M, Tesfai K, Madamba E, et al. Prevalence and Risk Factors Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Fibrosis Among Overweight Individuals: Implications for Screening Guidelines. Am J Gastroenterol. 2026. PMID: 42333597. doi:10.14309/ajg.0000000000004091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。